» Articles » PMID: 29361042

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)

Abstract

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling side effect of taxanes. Acetyl-L-carnitine (ALC) was unexpectedly found to increase CIPN in a randomized trial. We investigated the long-term patterns of CIPN among patients in this trial.

Methods: S0715 was a randomized, double-blind, multicenter trial comparing ALC (1000 mg three times a day) with placebo for 24 weeks in women undergoing adjuvant taxane-based chemotherapy for breast cancer. CIPN was measured by the 11-item neurotoxicity (NTX) component of the FACT-Taxane scale at weeks 12, 24, 36, 52, and 104. We examined NTX scores over two years using linear mixed models for longitudinal data. Individual time points were examined using linear regression. Regression analyses included stratification factors and the baseline score as covariates. All statistical tests were two-sided.

Results: Four-hundred nine subjects were eligible for evaluation. Patients receiving ALC had a statistically significantly (P = .01) greater reduction in NTX scores (worse CIPN) of -1.39 points (95% confidence interval [CI] = -2.48 to -0.30) than the placebo group. These differences were particularly evident at weeks 24 (-1.68, 95% CI = -3.02 to -0.33), 36 (-1.37, 95% CI = -2.69 to -0.04), and 52 (-1.83, 95% CI = -3.35 to -0.32). At 104 weeks, 39.5% on the ALC arm and 34.4% on the placebo arm reported a five-point (10%) decrease from baseline. For both treatment groups, 104-week NTX scores were statistically significantly different compared with baseline (P < .001).

Conclusions: For both groups, NTX scores were reduced from baseline and remained persistently low. Twenty-four weeks of ALC therapy resulted in statistically significantly worse CIPN over two years. Understanding the mechanism of this persistent effect may inform prevention and treatment strategies. Until then, the potential efficacy and harms of commonly used supplements should be rigorously studied.

Citing Articles

The Lives of Older People With Advanced Cancer Who Live Alone During Outpatient Cancer Chemotherapy: A Descriptive Qualitative Study.

Sugiyama R, Nakamura Y Nurs Health Sci. 2025; 27(1):e70076.

PMID: 40064605 PMC: 11893514. DOI: 10.1111/nhs.70076.


Coasting related to taxane-induced peripheral neuropathy in patients with breast cancer: a systematic review.

Kruse F, Bille M, Lendorf M, Vaabengaard S, Birk S Acta Oncol. 2025; 64():78-86.

PMID: 39815403 PMC: 11748177. DOI: 10.2340/1651-226X.2025.42109.


Acetyl-L-carnitine ameliorates atherosclerosis in LDLR mice by modulating cholesterol metabolism through SREBP2-dependent cholesterol biosynthesis.

Xing J, Du Z, Li F, Wang Y, Zhang Z, Gao X Front Nutr. 2024; 11:1509577.

PMID: 39737151 PMC: 11684389. DOI: 10.3389/fnut.2024.1509577.


Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.

Chen C, Zirpoli G, Budd G, Barlow W, Pusztai L, Hortobagyi G Cancer Chemother Pharmacol. 2024; 94(2):311-321.

PMID: 38814343 PMC: 11878155. DOI: 10.1007/s00280-024-04680-6.


Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.

Chen C, Zirpoli G, Barlow W, Budd G, McKiver B, Pusztai L J Natl Compr Canc Netw. 2023; 21(11):1172-1180.e3.

PMID: 37935109 PMC: 10976748. DOI: 10.6004/jnccn.2023.7062.


References
1.
Cella D, Peterman A, Hudgens S, Webster K, Socinski M . Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer. 2003; 98(4):822-31. DOI: 10.1002/cncr.11578. View

2.
Hershman D, Weimer L, Wang A, Kranwinkel G, Brafman L, Fuentes D . Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2010; 125(3):767-74. DOI: 10.1007/s10549-010-1278-0. View

3.
Jones S, Savin M, Holmes F, OShaughnessy J, Blum J, Vukelja S . Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006; 24(34):5381-7. DOI: 10.1200/JCO.2006.06.5391. View

4.
Rowinsky E, Chaudhry V, Forastiere A, Sartorius S, Ettinger D, Grochow L . Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993; 11(10):2010-20. DOI: 10.1200/JCO.1993.11.10.2010. View

5.
Ezendam N, Pijlman B, Bhugwandass C, Pruijt J, Mols F, Caroline Vos M . Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014; 135(3):510-7. DOI: 10.1016/j.ygyno.2014.09.016. View